TABLE 1

Anthranilate supplementation restores AQ production to the ΔprrF1,2 mutant

StrainNormalized concn [(μg/μl)/OD600]a
C7-PQSC9-PQSHHQNHQHQNONQNO
Wild type0.37 ± 0.030.52 ± 0.030.10 ± 0.040.25 ± 0.091.56 ± 0.056.59 ± 0.34
ΔprrF1,2 mutant0.33 ± 0.030.27 ± 0.05d0.04 ± 0.01b0.11 ± 0.02b0.83 ± 0.21d3.73 ± 0.84d
ΔprrF1,2 mutant + anthranilate0.53 ± 0.03d,f0.17 ± 0.02d,e0.40 ± 0.09c,f0.37 ± 0.05b,f2.93 ± 0.31d,f6.07 ± 0.76e
  • a The concentration of each AQ in the supernatants of the indicated strains grown in DTSB, with or without 500 μM anthranilate, as indicated, was determined by LC–MS-MS and normalized by culture density, as described in Materials and Methods. Significant differences were determined by two-tailed Student's t test. OD600, optical density at 600 nm.

  • b P < 0.05 for the ΔprrF1,2 mutant, with or without anthranilate, compared to the wild-type strain.

  • c P < 0.005 for the ΔprrF1,2 mutant, with or without anthranilate, compared to the wild-type strain.

  • d P < 0.0005 for the ΔprrF1,2 mutant, with or without anthranilate, compared to the wild-type strain.

  • e P < 0.005 for the ΔprrF1,2 mutant with versus without anthranilate.

  • f P < 0.0005 for the ΔprrF1,2 mutant with versus without anthranilate.